On the other hand, a reduced expression of ERCC1, as result of the C-allele, has been shown to correlate with better responses to platinum-based therapies in non small cell lung cancer (NSCLC) patients, whereas the T-allele was found to correlate with platinum-resistance in gastric, ovarian and cervical cancers [80–83] (Table 3). Here, ERCC1 is linked to non-small cell lung carcinoma.